Grid Therapeutics, LLC logo

Grid Therapeutics, LLC

Grid Therapeutics is a biotech startup developing cancer therapeutics by applying an innovative platform to develop completely human derived antibodies for the treatment of multiple cancer types.

Grid is spinout from Duke University and is based on the innovative science developed by Edward F. Patz, Jr., MD and his team at Duke University. Also, Dr. Edward F. Patz, Jr, is the co-founder and CEO of Grid Therapeutics.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://gridtherapeutics.com
Founded2014
Disease Focus
Development Stage
STOCK CODENon Listed
Address
215 Morris St., Suite 300,NC 27701
Durham
United States
Email
Contact Number
+1 919-987-7190

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/grid-therapeutics” connections=”true” suffix=””]

Grids Complement Factor H (CFH) asset is based upon an innovative platform that first identified tumor specific immunoglobulin G (IgG) antibodies from patients with early stage cancer who do not develop metastasis. A unique strategy was used to determine the sequence of its lead IgG3 antibody directly from single B cells isolated from cancer patients with the CFH antibody. The antibody not only directly kills tumor cells, without detrimental effects on normal tissues, but also modulates the adaptive immune response to attack tumor cells anywhere in the body.

In Aug 2017, Grid acquired the exclusive rights to all intellectual property, including relevant patents, related to Complement Factor H (CFH) antibodies as a cancer therapy, and diagnostics around CFH.

In April 2018, Grid Biosciences closed its undisclosed Series B financing, led by Milestone Holdings, a California-based venture company. Earlier in Sep 2017, Grid closed Series A Funding round led by Longview International, Ltd., a Singapore-based venture capital firm and Duke University.